HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy?

HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy?

HIV-PIs (HIV protease inhibitors) have proved to be of great benefit for the millions of people suffering from AIDS. However, one of the side effects of this component of combined highly active antiretroviral therapy is lipodystrophy, which affects a large number of the patients taking this class of...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Goulbourne, C, Vaux, D
Formato:	Journal article
Idioma:	English
Publicado em:	Portland Press 2010

Registros relacionados

The structural basis of ZMPSTE24-dependent laminopathies
por: Quigley, A, et al.
Publicado em: (2013)

The structural basis of ZMPSTE24-dependent laminopathies.
por: Quigley, A, et al.
Publicado em: (2013)

Prelamin A and ZMPSTE24 in premature and physiological aging
por: Howard J. Worman, et al.
Publicado em: (2023-12-01)

ZMPSTE24 Is Associated with Elevated Inflammation and Progerin mRNA
por: Moritz Messner, et al.
Publicado em: (2020-08-01)

Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24.
por: Jemima Barrowman, et al.
Publicado em: (2012-01-01)

Acquired and Inherited Lipodystrophies
Publicado em: (2004-06-01)

Lipodystrophy in HIV/AIDS patients with different levels of physical activity while on antiretroviral therapy
por: Aline Francielle Mota Segatto, et al.
Publicado em: (2011-08-01)

Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (Haart)
por: N. Sunil Kumar, et al.
Publicado em: (2015-07-01)

Inhibition of Arenavirus Entry and Replication by the Cell-Intrinsic Restriction Factor ZMPSTE24 Is Enhanced by IFITM Antiviral Activity
por: Robert J. Stott-Marshall, et al.
Publicado em: (2022-02-01)

运用二代测序技术产前诊断ZMPSTE24基因突变
por: 麦明琴, et al.
Publicado em: (2017-01-01)

The Senolytic Drug Fisetin Attenuates Bone Degeneration in the Zmpste24−/− Progeria Mouse Model
por: William S. Hambright, et al.
Publicado em: (2023-01-01)

Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
por: Ayako Nagayama, et al.
Publicado em: (2021-05-01)

Targeting CK2 eliminates senescent cells and prolongs lifespan in Zmpste24-deficient mice
por: Jie Zhang, et al.
Publicado em: (2024-05-01)

HIV-1 protease as a target for antiretroviral therapy
por: Windsor, Ian William.
Publicado em: (2019)

Acquired lipodystrophy following use of pembrolizumab
por: Maya Weitzen, et al.
Publicado em: (2024-12-01)

Acquired partial lipodystrophy associated with varicella
por: Zafer Kurugöl, et al.
Publicado em: (2009-12-01)

The Lipodystrophy Syndrome in HIV-Infected Children under Antiretroviral Therapy: A First Report from the Central Africa
por: Honoré Kalombayi Tshamala, et al.
Publicado em: (2019-01-01)

Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome.
por: Pere Domingo, et al.
Publicado em: (2010-11-01)

Influence of the duration of antiretroviral use on insulin resistance among people living with HIV with lipodystrophy
por: Thiago Rodrigues Faria Vitorazzi, et al.
Publicado em: (2018-12-01)

Defining substrate requirements for cleavage of farnesylated prelamin A by the integral membrane zinc metalloprotease ZMPSTE24.
por: Kaitlin M Wood, et al.
Publicado em: (2020-01-01)

The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B
por: Kamsi O. Odinammadu, et al.
Publicado em: (2023-12-01)

Lipodystrophy syndrome in HIV /
por: Wanke, Christine A., et al.
Publicado em: (2003)

The Place of protease inhibitors in antiretroviral treatment
por: S.B. Tenore, et al.

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
por: Bwakura-Dangarembizi, M, et al.
Publicado em: (2015)

Mass spectrometry captures off-target drug binding and provides mechanistic insights into the human metalloprotease ZMPSTE24
por: Mehmood, S, et al.
Publicado em: (2016)

ZMPSTE24 missense mutations that cause progeroid diseases decrease prelamin A cleavage activity and/or protein stability
por: Spear, ED, et al.
Publicado em: (2018)

Accelerated aging in articular cartilage by ZMPSTE24 deficiency leads to osteoarthritis with impaired metabolic signaling and epigenetic regulation
por: Jinlong Suo, et al.
Publicado em: (2023-05-01)

A Heterozygous ZMPSTE24 Mutation Associated with Severe Metabolic Syndrome, Ectopic Fat Accumulation, and Dilated Cardiomyopathy
por: Damien Galant, et al.
Publicado em: (2016-04-01)

ZMPSTE24 missense mutations that cause progeroid diseases decrease prelamin A cleavage activity and/or protein stability
por: Eric D. Spear, et al.
Publicado em: (2018-07-01)

Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch
por: Simeon Eche, et al.
Publicado em: (2021-03-01)

Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.
por: Cordula Frohoff, et al.
Publicado em: (2011-02-01)

Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
por: Musiime, V, et al.
Publicado em: (2014)

Barraquer–Simons Lipodystrophy Syndrome in an Otherwise Normal Child: A Rare Case of Acquired Partial Lipodystrophy
por: Kananbala Sahu, et al.
Publicado em: (2021-01-01)

A rare phenomenon of atypical lipodystrophy in a patient on HAART in the absence of a protease inhibitor regimen
por: Mohammed Mitha, et al.
Publicado em: (2010-11-01)

Overview of HIV-related lipodystrophy
por: T Marie Rossouw, et al.
Publicado em: (2013-02-01)

Hiv-associated lipodystrophy and exercise
por: E. Mutimura, et al.
Publicado em: (2006-02-01)

Restrictive Dermopathy Due to ZMPSTE24 Mutation: A Case Report with a Novel Finding of Corpus Callosum Agenesis
por: Minu Jose Chiramel, et al.
Publicado em: (2024-01-01)

Deficiency in ZMPSTE24 and resulting farnesyl–prelamin A accumulation only modestly affect mouse adipose tissue stores[S]
por: Patrick J. Heizer, et al.
Publicado em: (2020-03-01)

Inherited and acquired lipodystrophies: molecular-genetic and autoimmune mechanisms
por: Ekaterina L. Sorkina, et al.
Publicado em: (2018-04-01)

Acquired partial lipodystrophy: An atypical presentation with therapeutic challenge
por: Komali Garlapati, et al.
Publicado em: (2015-01-01)